Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Selinexor-based open-label phase 2b trial in refractory multiple myeloma
2020-000821-22Phase 2Active
- Sponsor
- Karyopharm Therapeutics Inc.
- Start
- May 2020
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of selinexor, dexamethasone and bortezomib in multiple myeloma (MM) (4 arms), sponsored by Karyopharm Therapeutics Inc. Primary endpoint: Overall response rate. Started May 2020; status: active.
02
Drugs
selinexordexamethasonebortezomib
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2020-000821-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-000821-22.